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E2Fs Regulate Adipocyte Differentiation
(Schoonjans et al., 1996). Ectopic expression of PPARLluis Fajas,1 Rebecca L. Landsberg,2
furthermore induces adipocyte differentiation (TontonozYolande Huss-Garcia,1 Claude Sardet,3
et al., 1994b). This primordial role of PPAR in adipocyteJacqueline A. Lees,2 and Johan Auwerx1,4
differentiation was further highlighted by the phenotype1Institut de Ge´ne´tique et de Biologie
observed in humans with mutations in the PPAR geneMole´culaire et Cellulaire
and by the characterization of PPAR-deficient miceCNRS/INSERM/ULP
(reviewed in Fajas et al., 2001).B.P. 163
Whereas much effort has been directed toward theF-67404 Illkirch cedex
understanding of the terminal stages of adipocyte differ-C.U. de Strasbourg
entiation, the molecular mechanisms underlying theFrance
transition between cell proliferation and differentiation2 Center for Cancer Research
of preadipocytes remain largely elusive. Reentry intoMassachusetts Institute of Technology
cell cycle is one of the key events taking place in earlyCambridge, Massachusetts 02139
adipogenesis, since inhibition of DNA synthesis at this3 Institut de Ge´ne´tique Mole´culaire
stage blocks differentiation (Patel and Lane, 2000;UMR 5535
Reichert and Eick, 1999). Like in most cells, the entryF-34293 Montpellier
of growth-arrested preadipocytes into S phase dependsFrance
on the activation of the G1 cyclins/cdks and the retino-
blastoma protein pRB-E2F pathway that controls the
G1/S transition of the cell cycle. E2F transcription fac-Summary
tors are the effectors of this pathway, and they control
the expression of genes involved in cell cycle progres-When preadipocytes reenter the cell cycle, PPAR ex-
sion, apoptosis, and DNA synthesis (for review see Helin,pression is induced, coincident with an increase in
1998; Sardet et al., 1997; Trimarchi and Lees, 2002).DNA synthesis, suggesting the involvement of the E2F
E2F activity is the result of the heterodimerization offamily of cell cycle regulators. We show here that E2F1
two proteins belonging to the E2F family (E2F1–6) andinduces PPAR transcription during clonal expansion,
the DP family (DP1 and 2), respectively (Dyson, 1998;whereas E2F4 represses PPAR expression during
Gaubatz et al., 1998). When bound to DNA, this hetero-terminal adipocyte differentiation. Using a combina-
dimeric complex exists either as free E2F/DP or formstion of in vivo experiments with knockout and chimeric
a larger complex that contains a member of the retino-animals and in vitro experiments, we demonstrate that
blastoma protein family (pRB, p107, or p130). pRB asso-the absence of E2F1 impairs, whereas depletion of
ciates with all E2Fs except for E2F5 and E2F6, whereasE2F4 stimulates, adipogenesis. E2Fs hence represent
p130 associates specifically with E2F4 and E2F5, andthe link between proliferative signaling pathways, trig-
p107 complexes associate exclusively with E2F4 (Co-gering clonal expansion, and terminal adipocyte differ-
brinik et al., 1993; Sardet et al., 1995). E2F complexesentiation through regulation of PPAR expression.
can activate (free heterodimers) or repress (large com-This underscores the complex role of the E2F protein
plexes) the transcription of E2F-responsive genes. Suchfamily in the control of both cell proliferation and differ-
repression is mediated through the recruitment of his-entiation.
tone deacetylases, which interact with proteins of the
pRB family (reviewed in Harbour and Dean, 2000). Infor-Introduction
mation about the role of the individual E2F family mem-
bers has been derived from both overexpression studies
Studies with preadipocyte cell lines, such as 3T3-L1 and the analysis of E2F-deficient mice and cells (re-
cells, have been instrumental in unraveling the molecu- viewed in Dyson, 1998; Trimarchi and Lees, 2002). These
lar mechanisms controlling adipocyte differentiation studies show that E2F1–3 play a key role in the activation
(Green and Kehinde, 1975). Upon reaching confluence, of E2F-responsive genes and, therefore, the induction
proliferating preadipocytes become growth arrested by of cellular proliferation. In contrast, E2F4 and E2F5 ap-
contact inhibition. Those contact inhibited preadipo- pear to be primarily involved in the repression of target
cytes reenter cell cycle after hormonal induction, arrest genes and are particularly relevant for the transition from
proliferation again, and, finally, undergo terminal adipo- cell proliferation to differentiation (Gaubatz et al., 2000;
cyte differentiation. Peroxisome proliferator-activated Humbert et al., 2000a; Rempel et al., 2000).
receptor  (PPAR) has been shown to be crucial in the The E2F and pRB family members appear to partici-
control of terminal adipocyte differentiation (Fajas et al., pate in the regulation of cell cycle events that are re-
1998b; Rosen et al., 2000). PPAR, upon activation by quired for adipogenesis. In growth-arrested preadipo-
either fatty acid derivatives or antidiabetic thiazolidined- cytes, E2F4 and E2F5 are complexed with p130, leading
iones, drives the expression of several adipocyte-spe- to repression of its target genes (for review, see Dyson,
cific genes, such as the fatty acid binding protein (aP2) 1998). Upon reentry into cell cycle of these growth-
(Tontonoz et al., 1994a) or lipoprotein lipase (LPL) arrested preadipocytes, p130, as well as the other mem-
bers of the retinoblastoma family, is phosphorylated by
the cyclin/cdk holoenzymes, releasing the E2F complex,4 Correspondence: auwerx@igbmc.u-strasbg.fr
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Figure 1. Expression of PPAR and Cell Cycle-Related Proteins during 3T3-L1 Differentiation
(A) Western blot analysis of whole-cell extracts prepared at different days of adipocyte differentiation of 3T3-L1 cells. The proteins detected
with specific antibodies are indicated.
(B) Analysis of PPAR protein expression and BrdU incorporation by immunofluorescence in postconfluent 3T3-L1 cells stimulated with
differentiation medium for 1 day as described under Experimental Procedures. Cells expressing PPAR are labeled in green (FITC), whereas
cells that have incorporated BrdU are labeled in red. Nuclei were stained with the Hoechst reagent (blue staining).
(C) Analysis of cyclin A and PPAR coexpression by immunofluorescence in 3T3-L1 cells induced to differentiate for 1 day. PPAR-expressing
cells, red; cyclin A-expressing cells, green. Nuclei were visualized with Hoechst staining.
resulting in the activation of the E2F target genes (Ri- and E2F1 were not detected during the later stages of
adipocyte differentiation, E2F4 protein levels remainedchon et al., 1997). After several rounds of DNA synthesis,
the cyclin-dependent kinase inhibitors, such as p21, elevated for at least 5 days after induction of differentia-
tion. At this time point, adipogenic markers, such asp27, and p18, are induced, and they mediate cell cycle
exit and maintain the irreversible growth arrest charac- the PPAR protein, were strongly expressed (Figure 1A,
bottom panel). Interestingly, PPAR expression wasteristic of terminal adipocyte differentiation (Morrison
and Farmer, 1999). PPAR and C/EBP have been switched on at the same time point as cyclin A and E2F1.
Consistent with reentry into cell cycle, p130 becameshown to contribute to this permanent cell cycle exit by
inhibiting the E2F DNA binding activity and upregulating and remained phosphorylated during clonal expansion
(Figure 1A). At a later stage during differentiation, p130the levels of p21, respectively (Altiok et al., 1997; Porse
et al., 2001; Timchenko et al., 1996). There is also evi- became hypophosphorylated and, thus, active (Figure
1A). Total pRB protein levels remained almost stabledence that pRB plays a positive role in adipocyte differ-
entiation through association and activation of C/EBP from day 1 of differentiation onward (Figure 1A). Most
of the pRB protein was hyperphosphorylated (Figure 1A).(Chen et al., 1996).
In this study, we show that the E2F proteins play a Next, 3T3-L1 cells at day 1 of differentiation were
incubated with BrdU to evaluate DNA synthesis. Visual-direct role in the regulation of early adipocyte differentia-
tion. E2F1 and 3 trigger the expression of PPAR during ization of the cells by fluorescence microscopy demon-
strated that cells which had incorporated BrdU alsothe early stages of adipogenesis, whereas E2F4 re-
presses expression of PPAR at the terminal stage of stained positive for PPAR protein (Figure 2B), indicat-
ing that PPAR expression coincided with active DNAadipocyte differentiation.
synthesis in these differentiating 3T3-L1 cells. A similar
experiment was performed using an anti-cyclin A anti-Results
body. Again, PPAR was coexpressed in the nucleus
with cyclin A, a marker of the S phase of the cell cyclePPAR Expression Coincides with Reentry
into Cell Cycle (Figure 2C). These results suggest that expression of
PPAR might be under the control of the same factorsWhen hormonally stimulated, confluent 3T3-L1 preadi-
pocytes reenter cell cycle before they undergo differen- that induce reentry into the cell cycle, i.e., the E2F family
of transcription factors.tiation (Green and Kehinde, 1975). We correlated the
expression of some cell cycle regulators and known
E2F target genes with the expression of PPAR during E2Fs Bind In Vitro to the PPAR1 Promoter
Computer-assisted sequence analysis of the regulatorydifferentiation of 3T3-L1 preadipocytes. Protein levels
of cyclin A, E2F1, and E2F4 were increased after 1 day regions of the human PPAR gene demonstrated the
presence of a consensus E2F binding site at positionof differentiation (Figure 1A). Whereas levels of cyclin A
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Figure 2. In Vitro Binding of E2F to the PPAR1 Promoter
(A) Schematic representation of the genomic structure of the 5 region of the human PPAR gene. Transcription initiation sites are indicated
by arrows and labeled 1, 2, and 3. Shaded boxes indicate exons. The E2F binding site in the PPAR1 promoter is depicted as a white
box. Comparison of this PPAR E2F site with the E2F binding site of classical E2F target genes is illustrated. Arrows indicate the DNA
fragments amplified in ChIP analysis.
(B) In vitro binding of E2F to the PPAR1 promoter. EMSA analysis of the radiolabeled E2F DNA binding site of the PPAR1 promoter incubated
with nuclear extracts of 3T3-L1 cells at the indicated times of differentiation. Composition of the different complexes is indicated. Double-
stranded cold oligonucleotides, representing either the PPAR1-E2F site (1-E2F), the mutated PPAR1-E2F site (1-E2Fmut), or the E2F
consensus binding site from the adenoviral E2 promoter (E2Fcons), were included in the competition assays (lanes 7–9). Only the retarded
complexes are shown.
(C) EMSA demonstrating the composition of the retarded complexes in nuclear extracts of 3T3-L1 cells at day 0 (left panel, lanes 1–4), day
1 (middle panel; lanes 5–8), or day 5 (right panel; lanes 9–12) of induction of differentiation. The antibodies used for the gel supershift are
indicated.
(D) Northern blot analysis of PPAR, aP2, and 36B4 mRNA expression at different times after induction of differentiation of 3T3-L1 preadipocytes.
215 in the PPAR1 promoter. The sequence of the E2F (Figure 2B, days 2–5). At day 5 after induction of differen-
tiation, the free E2F complex decreased in intensity, but,site in the PPAR1 promoter was identical to the E2F
binding site of the c-Myc promoter and highly similar to now, the predominant complex was again composed of
E2F4 and p130 (Figures 2B and 2C, lanes 9–12). Thesethe binding sites in the cyclins E and D1 or the adenoviral
E2 promoters (Figure 2A). Binding of E2F to the PPAR1 results hence suggest that E2F is able to bind in vitro
to the PPAR1 promoter. Furthermore, Northern blotpromoter was tested by electrophoretic mobility shift
assay (EMSA). Typical E2F complexes were bound to the analysis showed a good correlation between the pres-
ence of free E2F complexes bound to the PPAR1 E2Fradiolabeled PPAR-E2F site when whole-cell extracts
prepared at different times of the adipocyte differentia- response element and PPAR mRNA levels during adi-
pocyte differentiation of 3T3-L1 cells (Figure 2D). Thistion process were used. At day 0, the predominating
DNA binding complex (Figure 2B, day 0) was composed suggests that E2F could be responsible for triggering
PPAR expression early during adipogenesis.of E2F4 and p130 (Figure 2C, lanes 1–4). One day after
induction of differentiation, two different complexes
were detected: a slower-migrating band and a faster-
E2Fs Bind In Vivo to the PPAR1 Promotermigrating double complex (Figure 2B, day 1). Faster-
and Transactivate Its Expressionmigrating complexes contained the different free E2F
In order to demonstrate the occupancy of the PPAR1species (mainly E2F4), whereas E2F4, p107, and cyclin
promoter by E2F proteins in vivo in human cells, chroma-A/cdk2 formed the slow-migrating complex (Figure 2C,
tin immunoprecipitation assays (ChIP) were performedlanes 5–8 and data not shown). The pattern of E2F DNA
using either specific antibodies (anti-E2F4, anti-E2F1,binding observed at this time suggested that most of
or an anti-acetylated H4 antibody) or preimmune serum.the cells have already reentered cell cycle. Between
Whereas no amplification of the PPAR1 promoter wasdays 2 and 4 of differentiation, free E2F remained pre-
observed when nonspecific antibodies were useddominant, whereas the composition of the slow-migrat-
ing E2F complex changed from E2F/p107 to E2F/p130 (mock; Figure 3A, lanes 5 and 10), a specific fragment,
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Figure 3. In Vivo Binding of E2F4 to the PPAR1 Promoter and Transactivation Assays
(A) Chromatin immunoprecipitation (ChIP) assays demonstrating binding of E2F1 and E2F4 to the PPAR1 promoter. Cross-linked chromatin
from either confluent (left panel) or human primary preadipocytes differentiated during 3 days (right panel) was incubated with antibodies
against E2F4 (lanes 2 and 7), E2F1 (lanes 4 and 9), acetylated histone H4 (lanes 3 and 8), or without any antibody (mock, lanes 5 and 10).
Immunoprecipitates were analyzed by PCR using primers specific for the indicated promoters (see Figure 2A). As a control, a sample
representing 1% of the total chromatin was included in the PCR (input, lanes 1 and 6).
(B–C) E2Fs modulate the PPAR1 promoter. Relative luciferase activity as determined after transfection of NIH 3T3 cells with the reporter
constructs pGL31E2wt and pGL31E2mut. Cells were either transfected with an empty expression vector, with expression vectors for E2F1,
E2F4, DP1, p130, pRB, or E1A 13S, or with combinations of these vectors, as indicated. Values are the mean of three independent experiments.
An asterisk depicts statistically significant differences.
corresponding to the PPAR1 promoter, was amplified indicating that, at this stage of differentiation, the
PPAR3 promoter was also activated, although not di-when chromatin of cells that were stimulated to differen-
tiate was immunoprecipitated with either the anti-E2F4 rectly by binding of E2F (Figure 3A, lane 8).
To assess whether E2Fs can directly regulate the hu-(Figure 3A, lane 7) or the anti-E2F1 (Figure 3A, lane 9)
antibody. No amplification product was observed when man PPAR1 promoter activity, we cotransfected ex-
pression plasmids coding for E2F1, E2F4, DP1, pRB, orimmunoprecipitated chromatin from confluent nondif-
ferentiated human primary preadipocytes was used as p130 together with the pGL31E2wt luciferase reporter
vector, which contains the human PPAR1 promoterthe template (Figure 3A, lanes 2 and 4). Strikingly, the
same pattern of E2F1 and E2F4 binding was observed (Fajas et al., 1997). When NIH-3T3 cells were cotrans-
fected with either E2F1 (Figure 3B) or E2F4 (Figure 3C),when oligonucleotides corresponding to the cyclin D1
promoter were used to amplify the immunoprecipitated luciferase activity increased 5- and 4-fold, respectively,
relative to the basal activity of the hPPAR1 promoter.chromatin (Figure 3A, lanes 2, 4, 7, and 9). A different
fragment from the PPAR gene, covering the proximal This induction was substantially enhanced (up to 8-fold)
upon cotransfection with the heterodimeric partner ofPPAR3 promoter (Fajas et al., 1998a), could not be
amplified, either from confluent or differentiated cells, E2F, DP1. As expected for an E2F target gene, when a
constitutively active form of pRB or p130 was cotrans-when the anti-E2F1 or the anti-E2F4 antibody was used
(Figure 3A, lanes 2, 4, 7, and 9). The results of these ChIP fected with E2F1/DP1, the stimulatory effect on the
PPAR1 promoter was abrogated (Figures 3B and 3C).assays hence prove that E2F1 and E2F4 specifically
bind to the PPAR1 promoter in differentiating human This repressive effect of E2Fs of the PPAR1 promoter
was clearly dependent on the presence of the pocketadipocytes. ChIP assay also demonstrated the presence
of acetylated histone H4 on the PPAR1 and cyclin D1 proteins pRB and p130, since cotransfection of the ade-
noviral protein E1A 13S resulted in the abrogation of thepromoters (Figure 3A, lane 8), suggesting that the bind-
ing of E2Fs results in the activation of these promoters. repression (Figures 3B and 3C). Similar results were
observed when an E2F3 expression vector was usedInterestingly, when using an anti-acetylated histone H4
antibody, the PPAR3 promoter could also be amplified, (data not shown). Finally, to demonstrate that it is
E2Fs and Adipogenesis
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Figure 4. E2F1–3 Stimulate Adipogenesis
(A) Weight gain curves of E2F1/ (black
squares) and E2F1/ (black triangles) mice
fed with a high-fat diet. Each group was com-
posed of ten animals. Animals were weighed
every week for a period of 8 weeks.
(B) Food intake and weight of the epidydimal
fat pads (expressed as % of total body
weight) of the animals used in the experiment
described in A. Statistically significant differ-
ences (p  0.05) are indicated by an asterisk.
(C) Quantification of lipid incorporation by
measuring the intensity of Oil red O staining of
wild-type (WT), E2F1/, E2F3/, or E2F4/
MEFs stimulated to differentiate into adipo-
cytes. An asterisk indicates statistically sig-
nificant differences (p  0.05).
through binding to the PPAR1-E2F site that E2Fs mod- E2F4 Negatively Regulates Adipogenesis
The ChIP experiments showed that, in addition to E2F1,ulate the activity of the hPPAR1 promoter, we substi-
E2F4 associated with the PPAR promoter in vivo. Ourtuted four bases in the PPAR1-E2F site (from GCG
transient transfection assays showed that E2F4 acti-GGAAA to GCGGCCGC) to generate the pGL31E2mut
vates the pGL31 luciferase reporter, and this is re-reporter plasmid. Cotransfected E2F/DP1 was unable
pressed by the coexpression of p130 (Figure 3C), con-to stimulate the mutated pGL31E2mut reporter vector
firming that E2F4 can regulate the PPAR promoter.in NIH-3T3 cells (Figure 3B, black bars). In the same
However, since E2F4 behaves as an activating E2F whenexperiment, the wild-type promoter was induced (data
it is overexpressed, this assay did not reveal whethernot shown).
the endogenous E2F4 regulates PPAR expression and,
therefore, adipogenesis positively (through free E2F/DP
heterodimers) or negatively (through recruitments ofE2F1 and E2F3 Positively Regulate Adipogenesis
pRB family members and associated HDACs). To ad-We have shown that E2F1 and PPAR1 are expressed
dress this issue, we determined how the absence ofat the same time in the differentiation process and that
E2F4 affected adipogenesis. The E2F4/ mice areE2F1 binds and activates the PPAR1 promoter. To de-
highly susceptible to bacterial infections, and the re-termine whether the activating E2Fs, E2F1 and E2F3,
sulting abnormal feeding pattern precludes their use forplay a positive role in adipogenesis, we analyzed the
analysis of adipose tissue homeostasis in vivo (Humberteffects of E2F1 or E2F3 depletion either in mice or in
et al., 2000a; Rempel et al., 2000). As an alternativeprimary mouse embryonic fibroblasts (MEFs). Consis-
approach, we first evaluated the ability of E2F4/ MEFstent with a role for E2F1 in triggering PPAR expression
(Figures 4C and 5A) and ES cells (Figure 5B) to differenti-
and adipogenesis, E2F1/ mice were resistant to obe-
ate into adipocytes in vitro. In both cases, we saw a
sity induced by feeding them a high-fat diet for eight
significant increase in the number of Oil red O-positive
weeks, whereas E2F1/ mice increased their weight cells in the E2F4/, compared to the E2F4/, mono-
significantly upon this high-fat diet (Figure 4A). The dif- layers (Figures 4C, 5A, and 5B). This suggests that E2F4
ference in weight could be entirely attributed to differ- exerts a negative effect on adipogenesis.
ences in fat mass (Figure 4B). No significant differences To further explore this hypothesis, E2F4/ or E2F4/
were observed in food intake between the E2F1/ and 129 D3 ES cells were injected into C57BL/6 blastocysts,
the E2F1/ mice (Figure 4B). The phenotype of the which were then reimplanted in pseudopregnant wild-
E2F1/ animals suggested a problem in adipose tissue type mice in order to create chimeric progeny. Twelve
homeostasis. To test this notion, we compared the ca- mice of each genotype considered highly chimeric were
pacity of MEFs deficient in the various E2Fs to differenti- sacrificed, and several organs were harvested and ana-
ate into adipocytes in vitro in response to hormone stim- lyzed for the contribution of the ES cells to the composi-
ulation. Adipocytes were scored using Oil red O staining tion of the tissues, using GPI as a marker. Tissue analysis
to detect lipid droplets. Hormonally stimulated E2F1/ revealed only a minor contribution of the injected 129
and E2F3/ MEFs showed a slightly, but consistently, D3 E2F4/ES cells to the development of white adipose
reduced capacity to differentiate into adipocytes in vitro tissue of the chimeric mice (Figures 5C and 5D). In con-
compared to wild-type MEFs (Figure 4C). Taken to- trast, white adipose tissue from chimeric mice resulting
gether, these data suggest that E2F1–3 stimulate adipo- from injection of 129 D3 E2F4/ cells was composed
of at least 40% of the mutant cells (Figures 5C and 5D).genesis through activation of PPAR.
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Figure 5. E2F4 Inhibits Adipogenesis
(A) Oil red O staining comparing lipid accumulation in E2F4/ or E2F4/ MEFs induced to differentiate into adipocytes.
(B) Oil red O staining comparing lipid accumulation in E2F4/ or E2F4/ ES cells induced to differentiate into adipocytes as described in
Experimental Procedures. Quantification of lipid incorporation by measuring the intensity of Oil red O staining is indicated at the right.
(C) Protein electrophoresis followed by colorimetric detection of the two different GPI isoforms in adipose tissue (WAT) of chimeric mice. The
lower band, indicated by an open arrowhead, corresponds to the GPI isoform contributed by recipient C57Bl/6 blastocyst cells. The upper
band, indicated by a closed arrowhead, corresponds to the GPI isoform derived from microinjected E2F4/ (upper panel) or E2F4/ 129 D3
ES cells (bottom panel).
(D) Quantification of the relative contribution of the microinjected ES cells (WT, E2F4/) in the development of either adipose tissue (WAT)
or kidney.
Importantly, no significant differences in contribution primary preadipocytes at different stages of adipogen-
between E2F4/ and E2F4/ chimeras were observed esis by immunofluorescence microscopy (Figure 6 and
in some other tissues, such as kidney or pancreas (Fig- data not shown). Confluent, growth-arrested 3T3-L1
ure 5D and data not shown). Together with the in vitro preadipocytes displayed high levels of nuclear E2F4,
studies of the E2F4/ cells, the analysis of these chime- whereas E2F1 and PPAR were expressed at low to
ric mice proves that E2F4 has a negative effect on adi- undetectable levels (Figures 6A and 6B, 0 hr). Twenty-
pose tissue development. four hours after induction of differentiation, a significant
fraction of the cells expressed PPAR (Figures 6A and
6B, 24 hr). Significantly, the PPAR-positive cells allCoincidence of PPAR and E2F1 or E2F4
expressed high levels of nuclear E2F1 and E2F4 protein.Expression in the Nucleus Is Dependent
This is consistent with the idea that E2F1 activateson the Stage of Adipogenesis
PPAR expression (Figure 3B). Moreover, since the p130Significantly, our analysis of the endogenous E2F com-
protein has largely dissociated from E2F4 at this timeplexes shows that E2F4 associates with the hypophos-
(Figure 2B), it suggests that free E2F4 may also contrib-phorylated and, thus, active form of p130 prior to induc-
ute to the activation of PPAR. During the terminal differ-tion of adipogenesis, and the disappearance of this
entiation phase (96 hr), nuclear PPAR protein is ex-complex coincides with the induction of PPAR expres-
pressed in most, but not all, of the cells (Figures 6Asion on day 1 of differentiation (compare Figures 2B and
and 6B). By this stage, E2F1 is undetectable. This is1A). This suggests that E2F4 inhibits adipocyte differen-
consistent with the end of the clonal expansion phasetiation by repressing PPAR expression through its as-
and the declining expression of E2F1 (Figure 1A). Insociation with p130. It has been previously shown that
contrast, E2F4 is still expressed in all cells (Figure 6A).the free E2F4/DP complexes are predominantly nuclear,
However, at this stage, the majority of these cells havewhereas association with the p130 and pRB relocalizes
cytoplasmic, rather than nuclear, E2F4 (Figure 6A, ar-these complexes in the cytoplasm (Magae et al., 1996;
rowheads). Significantly, we saw a perfect correlationMuller et al., 2001; Verona et al., 1997). We therefore
between the localization of E2F4 and the expression ofcompared the expression and subcellular localization
of PPAR, E2F1, and E2F4 in 3T3-L1 cells and human PPAR: E2F4 was cytoplasmic in PPAR-positive cells
E2Fs and Adipogenesis
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Figure 6. Comparative Analysis of PPAR, E2F4, and E2F1 Expression by Immunofluorescence at Different Times of the Adipocyte Differentia-
tion Program
Confluent 3T3-L1 cells (A) or human primary preadipocytes (B) were stimulated to differentiate as described. At the indicated time points of
differentiation, cells were fixed and incubated with both anti-PPAR and anti-E2F4 (A) or anti-E2F1 (B) antibodies. PPAR protein was detected
with a Texas red-labeled secondary antibody (red labeling), whereas E2F4 and E2F1 proteins were detected with an FITC-labeled secondary
antibody (green labeling). Nuclear localization was assessed by Hoechst staining of the nuclei. The white arrow in panel (A) highlights the fact
that E2F4 nuclear localization in differentiating cells coincides with the absence of PPAR expression.
and nuclear in PPAR-negative cells (Figure 6A, arrow- Discussion
head). Thus, at the late stage of differentiation, expres-
sion of PPAR can occur in the complete absence of Differentiation of preadipocytes into adipocytes re-
quires that growth-arrested preadipocytes reenter theeither free E2F1 or free E2F4 complexes. Moreover, the
presence of nuclear E2F4 complexes correlates with the cell cycle before undergoing terminal differentiation.
This particular situation is underscored by the fact thatrepression of this responsive gene.
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Figure 7. Model of PPAR Regulation by E2Fs during Adipogenesis in the Presence or Absence of E2F4
In growth-arrested preadipocytes (day 0), the PPAR gene is silenced by E2F4-p130-HDAC complex. During the clonal expansion phase, at
least two pools of cells can be distinguished: cells in which E2F1–3 and possibly E2F4 trigger the expression of PPAR and cells in which
E2F4 is associated with a p107-HDAC repressor complex. In cells that are actively differentiating (Differentiation), E2F4 is exported to the
cytoplasm, and E2F1 is not expressed. This allows that other transcription factors, such as C/EBPs or ADD1/SREBP1, sustain the expression
of PPAR, resulting in the differentiation of the cells into adipocytes. When cells are terminally differentiated (Terminal differentiation), E2F4
represses the expression of PPAR, through association with p130/p107, which recruits HDACs to the PPAR promoter. Undifferentiated
preadipocytes, gray; differentiated adipocytes, orange.
adipocyte differentiation is essentially triggered by pro- Based on the appearance/disappearance and subcel-
lular localization of the individual E2F complexes duringliferative stimuli, such as insulin or cAMP. In this study,
we elucidate the molecular mechanisms operating at differentiation and the phenotypes of the E2F-deficient
mice and cells, we propose the following model of E2Fthe transition between cell proliferation and adipocyte
differentiation. Consistent with the previous observation action (Figure 7). In confluent preadipocytes, the E2F4/
p130 complex acts to repress the transcription of E2F-that a block of DNA synthesis during the clonal expan-
sion phase of adipocyte differentiation inhibits adipo- responsive genes, including PPAR. Hormonal stimula-
tion results in the loss of this repressive complex andgenesis (Patel and Lane, 2000; Reichert and Eick, 1999),
we have demonstrated that clonal expansion is accom- the induction of E2F1. This leads to the coordinate ex-
pression of the classic E2F target genes, the activationpanied by changes in the E2F complexes. Within 1 day
of hormonal induction, the suppressive E2F4/p130 com- of clonal expansion, the expression of PPAR, and,
thereby, activation of differentiation. Our data stronglyplex is completely lost, and there is a major induction
of the expression of the activating E2Fs, particularly suggest that free E2F1/DP is involved in the transcrip-
tional activation of PPAR. During the late stages ofE2F1. These changes correlated closely with the induc-
tion of E2F-responsive genes, like cyclin A, that are differentiation, the expression of PPAR clearly occurs
in the absence of nuclear E2F species. This is entirelyknown to be required for cellular proliferation. Signifi-
cantly, the master regulator of adipogenesis, PPAR, is consistent with previous observations that PPAR ex-
pression is regulated by other transcription factors, in-induced at the same time, and our data strongly suggest
that this is a bona fide E2F target gene. First, the E2F cluding C/EBPs and SREBP (Fajas et al., 1999; Saladin
et al., 1999). Importantly, at this stage, the E2F4/p130proteins bind to a consensus E2F DNA binding site in
the PPAR1 promoter both in vitro (EMSA) and in vivo complex reappears, and the presence of nuclear E2F4 is
clearly incompatible with PPAR expression. This raises(ChIP). Second, reporter assays confirm that the E2Fs
can regulate transcription from the PPAR1 promoter the possibility that the reformation of E2F4/p130 might
facilitate the “switching off” of PPAR that occurs inin a manner that is entirely dependent upon the identified
E2F binding site. Consistent with the hypothesis that terminally differentiated adipocytes. Significantly, the
opposing roles of E2F1–3 and E2F4 in the regulationthe E2F proteins play a direct role in the regulation of
PPAR expression, we also present genetic evidence of PPAR expression and, therefore, adipogenesis are
entirely consistent with the prevailing view that thesethat the individual E2F proteins have profound effects
upon adipocyte differentiation in vitro and in vivo. E2F1- proteins are involved in the activation or repression of
classic E2F-responsive genes, respectively (reviewed inand E2F3-deficient cells have a reduced capacity to
differentiate into adipocytes, and E2F1/ mice have Trimarchi and Lees, 2002). Moreover, our model fits with
the previous demonstration that adipogenesis is pro-limited fat accretion upon high-fat feeding. Thus, these
activating E2Fs play a positive role in adipogenesis. In moted by the combined loss of p107 and p130, the
major E2F4-associated proteins (Classon et al., 2000).contrast, E2F4 has a negative influence on the differenti-
ation process. E2F4-deficient MEFs and ES cells have However, a number of issues remain to be resolved.
First, since E2F4 remains in the nucleus during clonalan increased propensity to undergo adipogenesis.
Moreover, E2F4/ ES cells contribute at a significantly expansion, we cannot rule out the possibility that free
E2F4/DP complexes actually contribute to the activationhigher level to adipose than to other tissues of chimeric
mice. of PPAR. At least in transient transfection assays, E2F4
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Plasmids and Probescan transactivate the PPAR promoter in the absence
The PPAR, aP2, and 36B4 probes are described previously (Fajasof p130. The phenotype of the E2F4-deficient mice and
et al., 1997). For the construction of the expression vector pcDNA-cells simply shows that E2F4’s repressive activity is
E2F4, a BamHI/EcoRI fragment from pBabe-E2F4 (a kind gift of
dominant over any role it might play in activation. Sec- Dr. Helin) was inserted in the same sites of the pcDNA3 vector
ond, the E2F and pocket proteins have now been shown (Stratagene, La Jolla, CA). The CMV-DP1, CMV-E2F1, and p130
expression vectors were a gift from Dr. L. Le Cam. The PPAR1,to regulate adipogenesis through a number of different
PPAR2, and PPAR3 promoter reporter vectors have been pre-mechanisms that appear to affect cell cycle regulation
viously described (Fajas et al., 1997; Fajas et al., 1998a). The PPAR1and/or the differentiation process. For example, pRB
promoter reporter vector with a mutation in the E2F binding siteappears to be essential for both cell cycle exit and coop-
was constructed by site-directed mutagenesis using the indicated
eration with the C/EBP family members in the activation oligonucleotides.
of key transcriptional targets (Chen et al., 1996; Classon
et al., 2000; Hansen et al., 1999; Higgins et al., 1996). Cell Culture, Protein Extracts, Retroviral Infection,
Transfections, and Implantation of PreadipocytesThus, it will be important to establish the relative impor-
E2F1/, E2F3/, and E2F4/ and wild-type MEFs were describedtance of these various mechanisms and to determine
(Humbert et al., 2000a; Humbert et al., 2000b). NIH-3T3 and 3T3-L1how they are coordinated in vivo. Finally, it is currently
cells were grown in DMEM and 10% fetal calf serum (FCS). Humanunclear why PPAR is not expressed along with other
primary preadipocytes were purchased from Zen-Bio (Research Tri-
E2F-responsive genes in actively cycling cells. However, angle, NC) and maintained under the conditions specified by the
we envisage several possibilities. Chromatin remodeling provider. Cells were differentiated with DMEM, 10% serum, 0.5 mM
3-isobutyl-1-methylxanthine (IBMX), 10 g/ml insulin, and 1Mcould account for the silencing of the PPAR gene in
dexamethasone for 2 days. From day 3 on, cells were incubatedproliferating cells, as has been shown for other genes
with DMEM, 10% serum, 10 g/ml insulin, and 1 nM BRL 49,653. Oil(Krebs et al., 2000; Krebs et al., 1999). In addition, other
red O staining and quantification are described elsewhere (Ramirez-repressive protein complexes may specifically inhibit
Zacarias et al., 1992). Nuclear and whole-cell extracts were prepared
the expression of the PPAR gene in cycling cells. as described (Fajas et al., 1997). All transfections were performed
GATA-2, GATA-3, and AEBP1 are all good candidates using the Lipofectamine Plus reagent (GIBCO Life Technologies,
Rockville, MD). Luciferase activity was measured as described (Fa-for such a role (Tong et al., 2000; He et al., 1995). Alterna-
jas et al., 1997).tively, signaling through the Wnt-10b and Pref-1 (Notch-
like) pathway could render the PPAR gene refractory
ES Cells Differentiation, Chimeric and Knockout Miceto induction by E2Fs (Ross et al., 2000; Smas and Sul,
Generation and maintenance of E2F4/, E2F4/, and E2F4/ ES1993). Interestingly, the induction of PPAR expression
cells were described previously (Humbert et al., 2000a). ES cells
has been reported in a number of proliferative disorders, were differentiated according to Rosen et al. (Rosen et al., 1999).
such as colon cancer (DuBois et al., 1998), prostate For generation of chimeric mice, wild-type or E2F4/ ES cells were
injected into 4 day blastocysts from C57BL/6 mice and reimplantedadenocarcinoma (Mueller et al., 2000), and breast can-
into pseudopregnant wild-type mice. At 7 weeks of age, animalscer cells (Mueller et al., 1998; Samid et al., 2000). It is
were sacrificed, and the organs were harvested in 50 mM Tris-therefore tempting to speculate that the mechanism that
HCl and 0.1% Triton X-100. All materials for glucose phosphatenormally blocks PPAR expression in cycling cells is
isomerase (GPI) analysis were purchased from Helena Labotratories
somehow abrogated. (Beaumont, Texas). GPI analysis was performed as previously de-
In summary, our data show that E2F1–3 and E2F4 scribed (Nagy and Rossant, 1999). Briefly, cells derived from the
injected 129 D3 ES cells (E2F4/ and E2F4/) will have a differenthave opposing effects on adipocyte differentiation that
GPI isoform with different electrophoretic mobility than the cellsappears to be largely attributable to their differential
derived from the C57BL/6 recipient blastocysts. Quantification ofregulation of PPAR expression. This provides direct
the electrophoretic bands after an enzymatic colorimetric reactionsupport for the idea that the E2F and pRB family mem-
will be indicative of the relative composition of the analyzed tissue.
bers play a central role in coordinating the transition E2F1/ and E2F1/ mice were purchased from Jackson Labora-
between cell proliferation and terminal differentiation. tories (Bar Harbor, ME) and fed a high-fat diet (58% fat, 25% carbo-
hydrates, and 16% protein) for 8 weeks.Modulation of the activity of E2Fs might open up new
perspectives in the control of adipogenesis and meta-
Electrophoretic Mobility Shift Assays (EMSA) and Chromatinbolic diseases.
Immunoprecipitation (ChIP)
Cell extracts were incubated for 15 min at 21C in a total volume ofExperimental Procedures
20 l binding buffer [10 mM Tris-HCl (pH 7.9), 40 mM KCl, 10%
glycerol, 0.05% Nonidet P-40, 1 mM DTT, and 1 g poly(dI:dC)] inMaterials and Oligonucleotides
the presence of 1 ng of a T4-PNK end-labeled double-strandedThe oligonucleotides used for various experiments in this manu-
oligonucleotide probe. For gel supershift analysis, 2 g of antibodyscript are the following in (5 to 3 orientation): E2 consensus, GCA
were added to the reaction. DNA-protein complexes were separatedTAAGTTTCGCGCCCTTTCTCAG; E2F-PPAR1 site, GGACGCGG
by electrophoresis on a 4% polyacrylamide gel in 0.25	 TBE bufferGAAAGCCGGTGGCTCC; E2F-PPAR1 mutated, GGACGCGGCC
at 21C and 10 V/cm. Chromatin immunoprecipitation assays wereGCGCCGGTGGCTCC; ChIP PPAR1 forward, GGACGCGGGAA
performed as described previously (Takahashi et al., 2000). Briefly,AGCCGGTGGCTCC; ChIP PPAR1 reverse, GAGGGAGCGGCC
proteins were formaldehyde cross-linked to DNA in confluent humanCGGGCTCGG; ChIP PPAR3 forward, GTTAAGATTTGAAAGAAGC
primary preadipocytes before induction of differentiation or in cellsCGACAC; ChIP PPAR3 reverse, GGCTCTTCATGAGGCTTATTG
induced with differentiation medium for 3 days. Proteins were thenTAGA; ChIP cyclin D1 forward, CAGGCGCGGCGCCTCAGG
immunoprecipitated using the indicated antibodies, DNA was ex-GATGGC; ChIP cyclin D1 reverse, GTCCGTGTGACGTTACTG
tracted from the immunoprecipitates, and PCR amplification wasTTGTTA. Rosiglitazone (BRL 49,653) was a kind gift of Dr. R. Heyman
performed using promoter-specific oligonucleotide primers.of Ligand Pharmaceuticals (San Diego, CA). All chemicals, unless
stated otherwise, were purchased from Sigma (St. Louis). Antibodies
were purchased from Santa Cruz Biotechnology (Santa Cruz, CA) Immunofluorescence
For all immunofluorescence experiments, cells were grown onexcept for the anti-BrdU antibody, which was purchased from
Sigma. coverslips. For BrdU incorporation, cells were incubated 4 hr in the
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presence of BrdU, and an additional treatment of the cells with Gaubatz, S., Lindeman, G.J., Ishida, S., Jakoi, L., Nevins, J.R., Living-
ston, D.M., and Rempel, R.E. (2000). E2F4 and E2F5 play an essential1.5 N HCl for 10 min at 21C was performed. After fixation and
permeabilization with methanol, cells were incubated with the indi- role in pocket protein-mediated G1 control. Mol. Cell 6, 729–735.
cated antibodies. Preparations were then incubated with a combina- Gaubatz, S., Wood, J.G., and Livingston, D.M. (1998). Unusual prolif-
tion of Texas red-conjugated anti-mouse IgG and FITC-conjugated eration arrest and transcriptional control properties of a newly dis-
anti-rabbit IgG. covered E2F family member, E2F-6. Proc. Natl. Acad. Sci. USA 95,
9190–9195.
Northern and Western Blot Analysis Green, H., and Kehinde, O. (1975). An established preadipose cell
SDS-PAGE and electrotransfer were performed as described line and its differentiation in culture II. Factors affecting adipose
(Schoonjans et al., 1996). The membranes were blocked overnight conversion. Cell 5, 19–27.
in blocking buffer (20 mM Tris, 100 mM NaCl, 1% Tween-20, and
Hansen, J.B., Petersen, R.K., Larsen, B.M., Bartkova, J., Alsner,
10% skim milk). Filters were first incubated 4 hr at 21C with the
J., and Kristiansen, K. (1999). Activation of peroxisome proliferator
indicated antibody and then for 1 hr at 21C with a peroxidase
activated receptor  bypasses the function of the retinoblastoma
conjugate secondary antibody. The complex was visualized with
protein in adipocyte differentiation. J. Biol. Chem. 274, 2386–2393.
4-chloro-1-naphtol as reagent. Northern blots were hybridized with
Harbour, J.W., and Dean, D.C. (2000). The Rb/E2F pathway: ex-PPAR, aP2, and 36B4 cDNAs and visualized as described (Schoon-
panding roles and emerging paradigms. Genes Dev. 14, 2393–2409.jans et al., 1996).
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